{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T16:54:16Z","timestamp":1775926456478,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ijid.2021.04.036","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T23:12:40Z","timestamp":1618960360000},"page":"295-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7379-353X","authenticated-orcid":false,"given":"Min","family":"Qiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weicong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengmin","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqiu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-9807","authenticated-orcid":false,"given":"Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ijid.2021.04.036_bib0005","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.celrep.2015.09.059","article-title":"Bactericidal antibiotics induce toxic metabolic perturbations that lead to cellular damage","volume":"13","author":"Belenky","year":"2015","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.ijid.2021.04.036_bib0010","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1099\/mic.0.000733","article-title":"Automated detection of bacterial growth on 96-well plates for high-throughput drug susceptibility testing of Mycobacterium tuberculosis","volume":"164","author":"Fowler","year":"2018","journal-title":"Microbiology (Reading)"},{"issue":"3","key":"10.1016\/j.ijid.2021.04.036_bib0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1248\/cpb.c17-00717","article-title":"Discovery of a novel fluoroquinolone antibiotic candidate WFQ-228 with potent antimicrobial activity and the potential to overcome major drug resistance","volume":"66","author":"Hirano","year":"2018","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"9","key":"10.1016\/j.ijid.2021.04.036_bib0020","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jmoldx.2020.06.010","article-title":"Specific gyrA gene mutations correlate with high prevalence of discordant levofloxacin resistance in Mycobacterium tuberculosis isolates from Beijing, China","volume":"22","author":"Huo","year":"2020","journal-title":"J Mol Diagn"},{"issue":"8","key":"10.1016\/j.ijid.2021.04.036_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa279","article-title":"Interpretation of discordant rifampicin susceptibility test results obtained using GeneXpert vs phenotypic drug susceptibility testing","volume":"7","author":"Huo","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.036_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijid.2020.01.021","article-title":"Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene","volume":"92","author":"Huo","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1016\/j.ijid.2021.04.036_bib0035","first-page":"2274","article-title":"Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system","volume":"68","author":"Isaeva","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ijid.2021.04.036_bib0040","first-page":"282","article-title":"Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance","volume":"14","author":"Kam","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.ijid.2021.04.036_bib0045","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1038\/s41467-019-10975-7","article-title":"Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.ijid.2021.04.036_bib0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.ijid.2021.04.036_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02516-18","article-title":"Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations","volume":"63","author":"Sarathy","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2021.04.036_bib0060","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/cid\/cix422","article-title":"Impact of fluoroquinolone use on mortality among a cohort of patients with suspected drug-resistant tuberculosis","volume":"65","author":"Seifert","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijid.2021.04.036_bib0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1574886308666140106154754","article-title":"Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles","volume":"9","author":"Sousa","year":"2014","journal-title":"Curr Drug Saf"},{"issue":"3","key":"10.1016\/j.ijid.2021.04.036_bib0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.diagmicrobio.2013.11.010","article-title":"Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values","volume":"78","author":"Tato","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.036_bib0075","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijid.2016.10.026","article-title":"Classifying new anti-tuberculosis drugs: rationale and future perspectives","volume":"56","author":"Tiberi","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2021.04.036_bib0080","series-title":"Global tuberculosis report 2020","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.ijid.2021.04.036_bib0085","series-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019"},{"issue":"1","key":"10.1016\/j.ijid.2021.04.036_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169413","article-title":"Assessment of a 96-well plate assay of quantitative drug susceptibility testing for Mycobacterium tuberculosis complex in China","volume":"12","author":"Xia","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ijid.2021.04.036_bib0095","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jinf.2017.12.017","article-title":"Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China","volume":"76","author":"Xu","year":"2018","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.ijid.2021.04.036_bib0100","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.06288-11","article-title":"Targeting persisters for tuberculosis control","volume":"56","author":"Zhang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2021.04.036_bib0105","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/AAC.01228-13","article-title":"Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China","volume":"58","author":"Zhang","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221003477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221003477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:59:02Z","timestamp":1761119942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221003477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":21,"alternative-id":["S1201971221003477"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.04.036","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}